- US-listed companies
- Verona Pharma plc
- Income statement
Verona Pharma plc【VRNA】Income statement
Market cap
$72.8B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | 40 | 0 | - | 42 |
| Revenue growth (%) | - | - | - | - | |
| Cost of revenue | - | - | 0 | - | - |
| Gross profit | - | - | 0 | - | - |
| Gross margin (%) | - | - | - | - | |
| Research & development | 45 | 79 | 49 | 17 | 45 |
| Operating margin (%) | - | - | |||
| Operating expenses | 74 | 113 | 76 | 68 | 197 |
| Operating income | -74 | -73 | -76 | -68 | -155 |
| Income before tax | -65 | -56 | -68 | -54 | -163 |
| Pretax margin (%) | - | -139 | -14,945 | - | -385.8 |
| Provision for income taxes | 0 | -0 | 0 | 0 | 10 |
| Effective tax rate (%) | |||||
| Net income | -65 | -56 | -69 | -54 | -173 |
| Net income margin (%) | - | - | |||
| Earnings per share | - | - | -0.13 | -0.09 | -0.27 |
| Diluted EPS | - | - | -0.13 | -0.09 | -0.27 |
| EBITDA | |||||
| EBITDA margin (%) | - | - |